Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy—a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines

Supportive Care in Cancer

Volumn 23, Issue 1, 2015, Pages 273-282

  Yu, Shiying ^a   Burke, Thomas A ^b   Chan, Alexandre ^c   Kim, Hoon Kyo ^d   Hsieh, Ruey Kuen ^e   Hu, Xichun ^f   Liang, Jin Tung ^g   Baños, Ana ^h   Spiteri, Carmel ⁱ   Keefe, Dorothy M K ^j  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b MERCK RESEARCH LABORATORIES   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d The Catholic University of Korea   (South Korea)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

^f FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h OptumInsight   (Sweden)

ⁱ Merck Sharp and Dohme (Australia)   (Australia)

^j UNIVERSITY OF ADELAIDE   (Australia)

more..

Author keywords

Antiemetic; Chemotherapy; Nausea; Observational; Prescribing patterns; Vomiting

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; DEXAMETHASONE; DOMPERIDONE; FOSAPREPITANT; GRANISETRON; HALOPERIDOL; LANSOPRAZOLE; METHYLPREDNISOLONE; METOCLOPRAMIDE; OMEPRAZOLE; ONDANSETRON; PALONOSETRON; PANTOPRAZOLE; PROCHLORPERAZINE; PYRIDOXINE; RAMOSETRON; TROPISETRON; CORTICOSTEROID; NEUROKININ 1 RECEPTOR ANTAGONIST; SEROTONIN 3 ANTAGONIST;

ADULT; ARTICLE; AUSTRALIA; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHINA; CORTICOSTEROID THERAPY; DESCRIPTIVE RESEARCH; DRUG USE; FEMALE; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HIGHLY EMETOGENIC CHEMOTHERAPY; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MODERATELY EMETOGENIC CHEMOTHERAPY; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PROPHYLAXIS; PROSPECTIVE STUDY; SINGAPORE; SOUTH KOREA; TAIWAN; AGED; ASIA; CHEMICALLY INDUCED; CLINICAL PRACTICE; CLINICAL PROTOCOL; MIDDLE AGED; NAUSEA; NEOPLASMS; PATIENT; VOMITING;

ADRENAL CORTEX HORMONES; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; ASIA; CLINICAL PROTOCOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; NEUROKININ-1 RECEPTOR ANTAGONISTS; PATIENTS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; QUALITY OF HEALTH CARE; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING;

EID: 84918802299     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2372-3     Document Type: Article

References (28)

1. Multinational Association of Supportive Care in Cancer (MASCC) (2013) MASCC/ESMO Antiemetic guideline 2013. http://www.mascc.org/assets/documents/mascc_guidelines_english_2013.pdf. Accessed 24 February 2014
2. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189–4198. doi:10.1200/JCO.2010.34.4614
3. National Comprehensive Cancer Network (2013) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Antiemesis, Version I.2014. http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed 24 February 2014
4. China Committee of Rehabilitation and Palliative Care (2012) Cancer therapy induced nausea and vomiting guidelines. Peking Union Medical College Press, Beijing
5. Cancer Institute of New South Wales (eviQ) (2014) Prevention of chemotherapy induced nausea and vomiting. eviQ Cancer Treatments Online. https://www.eviq.org.au/Protocol/tabid/66/id/7/Default.aspx. Accessed 30 January 2014
6. Nolte MJ, Berkery R, Pizzo B, Baltzer L, Grossano D, Lucarelli CD, Kris MG (1998) Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. J Clin Oncol 16(2):771–778
7. Hayashi T, Ikesue H, Esaki T, Fukazawa M, Abe M, Ohno S, Tomizawa T, Oishi R (2012) Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation. Support Care Cancer 20(8):1805–1810. doi:10.1007/s00520-011-1278-6
8. Aapro M, Molassiotis A, Dicato M, Pelaez I, Rodriguez-Lescure A, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986–1992. doi:10.1093/annonc/mds021
9. Gilmore JW, Peacock NW, Gu A, Szabo S, Rammage M, Sharpe J, Haislip ST, Perry T, Boozan TL, Meador K, Cao X, Burke TA (2014) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract 10(1):68–74. doi:10.1200/JOP.2012.000816
10. Miura S, Watanabe S, Sato K, Makino M, Kobayashi O, Miyao H, Iwashima A, Okajima M, Tanaka J, Tanaka H, Kagamu H, Yokoyama A, Narita I, Yoshizawa H (2013) The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy. Support Care Cancer 21(9):2575–2581. doi:10.1007/s00520-013-1835-2
11. Dranitsaris G, Leung P, Warr D (2001) Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Care Cancer 9(8):611–618
12. Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202. doi:10.1016/j.ejphar.2013.09.073
13. Keefe D, Chan A, Kim H-K, Hsieh R-K, Yu S, Wang YC, Nicholls R, Burke TA (2014) Rationale and design of the Pan Australasian ChemoTherapy InduCed Emesis burden of illness study. Support Care Cancer: under consideration
14. Hsieh R-K, Chan A, Kim H-K, Yu S, Kim J-G, Lee M-A, Dalén J, Jung H, Chung J-M, Burke TA, Keefe D (2014) The incidence of chemotherapy-induced nausea and vomiting within and across Asia Pacific countries following moderately and highly emetogenic chemotherapy. Support Care Cancer: under consideration
15. Uppsala Monitoring Center (2010) WHO Drug Dictionary version 3, 01 September 2010. http://www.umc-products.com/?&mn1=1105. Accessed 24 February 2014
16. American Society of Clinical Oncology (ASCO) The Quality Oncology Practice Initiative (QOPI). http://qopi.asco.org/. Accessed 24 February 2014
17. Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, Lindenauer PK (2003) Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 21(7):1373–1378
18. Burmeister H, Aebi S, Studer C, Fey MF, Gautschi O (2012) Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Support Care Cancer 20(1):141–147. doi:10.1007/s00520-010-1079-3
19. The Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332(1):1–5
20. The Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342(21):1554–1559
21. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–243. doi:10.1093/annonc/mdq194
22. Aapro M, Fabi A, Nole F, Medici M, Steger G, Bachmann C, Roncoroni S, Roila F (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21(5):1083–1088. doi:10.1093/annonc/mdp584
23. Horne R, Graupner L, Frost S, Weinman J, Wright SM, Hankins M (2004) Medicine in a multi-cultural society: the effect of cultural background on beliefs about medications. Soc Sci Med 59(6):1307–1313. doi:10.1016/j.socscimed.2004.01.009
24. Chan A, Low XH, Yap KY (2012) Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy. J Manag Care Pharm 18(5):385–394
25. Australian Department of Health Pharmaceutical Benefits Scheme (PBS). http://www.pbs.gov.au. Accessed 24 February 2014
26. Korean National Health Insurance Corporation. www.nhic.or.kr/portal/site/eng/. Accessed 24 February 2014
27. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR (1999) Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282(15):1458–1465
28. Grunberg SM (2009) Obstacles to the implementation of antiemetic guidelines. J Natl Compr Cancer Netw 7(5):601–605